Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference

Reuters

06-22

Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference

Innovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's $(ADA.AU)$ 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545438805"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545438805\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545438805?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-22 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545438805","market":"nz","top_or_hot":-1,"title":"Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-22 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nNDL95NyDN:1","article_id":"2545438805","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545438805","pubTimestamp":1750556184,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference. Innovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's  85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp, improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1589":"北水核心资产","01911":"华兴资本控股","01801":"信达生物","BK1147":"投资银行业与经纪业"},"translate_title":"信达生物在ADA会议上公布靶向心血管风险标志物的新型抗体-肽偶联物有希望的临床前研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n    \n\nInnovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's $(ADA.AU)$ 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}